MRK

SEC source: 0001127602-23-021936 · form4.xml · nonDerivative · entry 2

Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 0

SEC source: 0001127602-23-021936 · form4.xml · nonDerivative · entry 1

Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,569.325

SEC source: 0001127602-23-020050 · form4.xml · derivative · entry 2

Coe Mary Ellen · CIK 0001691304 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,851.3335

Underlying: Common Stock · 259.9879 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001127602-23-020098 · form4.xml · derivative · entry 2

GLOCER THOMAS H · CIK 0001140799 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,340.1263

Underlying: Common Stock · 389.9818 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001127602-23-020136 · form4.xml · derivative · entry 2

Seidman Christine E · CIK 0001805745 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,451.4933

Underlying: Common Stock · 70.4134 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001127602-23-020143 · form4.xml · derivative · entry 2

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,484.7685

Underlying: Common Stock · 259.9879 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001127602-23-017140 · form4.xml · derivative · entry 2

BAKER DOUGLAS M JR · CIK 0001198753 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,412.1561

Underlying: Common Stock · 1,980.7329 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001127602-23-017145 · form4.xml · derivative · entry 2

Coe Mary Ellen · CIK 0001691304 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,591.3456

Underlying: Common Stock · 1,980.7329 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001127602-23-017149 · form4.xml · derivative · entry 2

Craig Pamela J. · CIK 0001232910 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,797.5044

Underlying: Common Stock · 1,980.7329 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001127602-23-017153 · form4.xml · derivative · entry 2

GLOCER THOMAS H · CIK 0001140799 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,950.1445

Underlying: Common Stock · 1,980.7329 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001127602-23-017171 · form4.xml · derivative · entry 2

Mayo Stephen · CIK 0001849061 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,430.3599

Underlying: Common Stock · 1,980.7329 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001127602-23-017183 · form4.xml · derivative · entry 2

Rothman Paul · CIK 0001601332 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,797.5164

Underlying: Common Stock · 1,980.7329 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001127602-23-017186 · form4.xml · derivative · entry 2

RUSSO PATRICIA F · CIK 0001023219 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,851.7344

Underlying: Common Stock · 1,980.7329 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001127602-23-017190 · form4.xml · derivative · entry 2

Seidman Christine E · CIK 0001805745 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,381.0799

Underlying: Common Stock · 1,980.7329 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001127602-23-017202 · form4.xml · derivative · entry 2

Warden Kathy J · CIK 0001559112 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,228.9874

Underlying: Common Stock · 1,980.7329 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001127602-23-017206 · form4.xml · derivative · entry 2

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,224.7806

Underlying: Common Stock · 1,980.7329 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001127602-23-017218 · form4.xml · derivative · entry 2

THULIN INGE G · CIK 0001263739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,973.6684

Underlying: Common Stock · 1,980.7329 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001127602-23-017227 · form4.xml · derivative · entry 2

LAVIZZO-MOUREY RISA J · CIK 0001034465 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,100.3274

Underlying: Common Stock · 1,980.7329 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001127602-23-014739 · form4.xml · derivative · entry 9

Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,875 shares

Expires 2027-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.

SEC source: 0001127602-23-014739 · form4.xml · derivative · entry 8

Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 951

Underlying: Common Stock · 949 shares

Expires 2024-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

SEC source: 0001127602-23-014739 · form4.xml · nonDerivative · entry 6

Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,709.972

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.5000 to $117.6200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-23-014739 · form4.xml · nonDerivative · entry 5

Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,584.972

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-014739 · form4.xml · nonDerivative · entry 4

Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,709.972

SEC source: 0001127602-23-014739 · form4.xml · nonDerivative · entry 3

Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,035.972

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-014745 · form4.xml · derivative · entry 6

LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 816

Underlying: Common Stock · 813 shares

Expires 2024-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

SEC source: 0001127602-23-014745 · form4.xml · nonDerivative · entry 4

LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,141.693

SEC source: 0001127602-23-014745 · form4.xml · nonDerivative · entry 3

LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,420.693

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-014751 · form4.xml · derivative · entry 7

Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 887

Underlying: Common Stock · 885 shares

Expires 2024-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

SEC source: 0001127602-23-014751 · form4.xml · nonDerivative · entry 4

Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,039.999

SEC source: 0001127602-23-014751 · form4.xml · nonDerivative · entry 3

Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,475.999

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-014755 · form4.xml · derivative · entry 3

Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 912

Underlying: Common Stock · 907 shares

Expires 2024-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

SEC source: 0001127602-23-014755 · form4.xml · nonDerivative · entry 2

Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,759.748

SEC source: 0001127602-23-014755 · form4.xml · nonDerivative · entry 1

Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,206.748

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-014759 · form4.xml · nonDerivative · entry 1

Zachary Jennifer · CIK 0001737231 · EVP, General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,127.593

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.3400 to $117.6800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-23-014739 · form4.xml · derivative · entry 7

Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,608

Underlying: Common Stock · 803 shares

Expires 2025-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024 and 5/3/2025.

SEC source: 0001127602-23-014739 · form4.xml · nonDerivative · entry 2

Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,086.972

SEC source: 0001127602-23-014739 · form4.xml · nonDerivative · entry 1

Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,362.972

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-014745 · form4.xml · derivative · entry 5

LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,378

Underlying: Common Stock · 689 shares

Expires 2025-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025.

SEC source: 0001127602-23-014745 · form4.xml · nonDerivative · entry 2

LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,607.693

SEC source: 0001127602-23-014745 · form4.xml · nonDerivative · entry 1

LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,843.693

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-014764 · form4.xml · derivative · entry 12

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,151

Underlying: Common Stock · 12,000 shares

Expires 2030-04-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F8 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.

SEC source: 0001127602-23-014764 · form4.xml · derivative · entry 11

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,151

Underlying: Common Stock · 15,000 shares

Expires 2030-04-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F8 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.

SEC source: 0001127602-23-014764 · form4.xml · derivative · entry 10

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,258

Underlying: Common Stock · 12,000 shares

Expires 2031-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F7 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

SEC source: 0001127602-23-014764 · form4.xml · derivative · entry 9

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,366

Underlying: Common Stock · 13,000 shares

Expires 2029-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F6 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.

SEC source: 0001127602-23-014764 · form4.xml · nonDerivative · entry 8

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,685.145

SEC source: 0001127602-23-014764 · form4.xml · nonDerivative · entry 7

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,085.145

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-014764 · form4.xml · nonDerivative · entry 6

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,085.145

F1 · kind: These exercise and sale transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.0000 to $119.0800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-23-014764 · form4.xml · nonDerivative · entry 5

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,085.145

F1 · kind: These exercise and sale transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.0000 to $119.0600, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-23-014764 · form4.xml · nonDerivative · entry 4

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,085.145

F1 · kind: These exercise and sale transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.0000 to $119.1300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-23-014764 · form4.xml · nonDerivative · entry 3

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,085.145

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These exercise and sale transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2023.